Jane Robertson
AstraZeneca · AstraZeneca, Alderley Park
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
25
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
1 more share only the name and are not shown
Trial papers
261
PubMed author-name match
Trials
Studies that name Jane Robertson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:40 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01081951 · Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian CancerAstraZeneca · active not recruiting · Ovarian Cancer · study director
- Ph2NCT01078662 · Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation PatsAstraZeneca · completed · Ovarian, Breast, Prostate · study director
- Ph2NCT01063517 · Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer PatientsAstraZeneca · completed · Gastric Cancer · study director
- Ph2NCT00912743 · Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) StatusAstraZeneca · completed · Colorectal Cancer · study director
- Ph1NCT00819221 · AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid TumoursAstraZeneca · terminated · Solid Tumors · study director
- Ph1NCT00782574 · Phase I AZD2281/Cisplatin in Advanced Solid Tumour PatientsAstraZeneca · completed · Advanced Solid Tumors · study director
- Ph1NCT00777582 · Phase I Comparative Bioavailability StudyAstraZeneca · active not recruiting · Solid Tumors · study director
- Ph3NCT00777153 · Cediranib in Combination With Lomustine Chemotherapy in Recurrent GlioblastomaAstraZeneca · completed · Recurrent Glioblastoma · study director
- Ph1NCT00748891 · DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)AstraZeneca · completed · Cancer · study director
- Ph2NCT00679783 · Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast CancerAstraZeneca · completed · Ovarian Carcinoma, Breast Cancer · study director
- Ph2NCT00628251 · Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian CancerAstraZeneca · completed · Ovarian Neoplasms · study director
- Ph1NCT00539331 · Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer PatientsAstraZeneca · terminated · Carcinoma, Non-Small-Cell Lung · study director
- Ph1NCT00516724 · Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or PaclitaxelAstraZeneca · completed · Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin · study director
- Ph1NCT00516373 · A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)AstraZeneca · completed · Ovarian Neoplasms, BRCA1 Protein, BRCA2 Protein · study director
- Ph1NCT00515866 · Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic CancerAstraZeneca · completed · Pancreatic Neoplasms · study director
- Ph1NCT00503204 · Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain TumourAstraZeneca · completed · Recurrent Glioblastoma, Brain Tumor · study director
- Ph1NCT00503477 · A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in JapanAstraZeneca · completed · Advanced Solid Tumor · study director
- Ph1NCT00502567 · A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid TumorsAstraZeneca · completed · Advanced Solid Tumor · study director
- Ph1/Ph2NCT00494221 · A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOXAstraZeneca · completed · Metastatic Colorectal Cancer · study director
- Ph2NCT00423332 · Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell CarcinomaAstraZeneca · completed · Renal Cell Carcinoma · study director
- Ph3NCT00399035 · Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal CancerAstraZeneca · completed · Metastatic Colorectal Cancer · study director
- Ph2NCT00385203 · The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).AstraZeneca · completed · Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas · study director
- Ph2/Ph3NCT00384176 · First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOXAstraZeneca · completed · Colorectal Cancer · study director
- Ph2NCT00278889 · Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)AstraZeneca · completed · Colorectal Cancer · study director
- Ph2NCT00264004 · Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid TumoursAstraZeneca · completed · Tumors · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:40 UTC. The ranking covers the 200 most relevant of 261 PubMed records, and a shared surname and initials can bring in a namesake. All 261 on PubMed
- Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.N Engl J Med · 19801,387 citationsRCR 37.5
- Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.J Clin Oncol · 2002487 citationsRCR 9.6
- Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.Cancer · 2001429 citationsRCR 10.0
- 426 citationsRCR 12.8
- Captopril in heart failure. A double blind controlled trial.Br Heart J · 1984414 citationsRCR 17.2
- 391 citationsRCR 8.3
- 379 citationsRCR 11.1
- 280 citationsRCR 5.8
- Association between peridural scar and recurrent radicular pain after lumbar discectomy: magnetic resonance evaluation. ADCON-L European Study Group.Neurosurgery · 1996270 citationsRCR 13.4
- Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.J Clin Oncol · 2007261 citationsRCR 5.9